FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Quiz - MDSpire

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis

Effectiveness of eHealth Interventions in Alleviating Burden on Informal Caregivers of People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials

An interpretable TimeMIL framework for fNIRS: differential diagnosis between schizophrenia and bipolar disorder